Shuttle Pharmaceuticals Holdings, Inc.
shuttlepharma.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Shuttle Pharmaceuticals has undergone a radical and concerning business transformation, pivoting away from its core pharmaceutical business into cryptocurrency mining (United Dogecoin) and AI drug discovery software (Molecule.ai), while simultaneously winding down its Ropidoxuridine clinical trials. The company disclosed ineffective disclosure controls and multiple material weaknesses in internal controls, alongside significant dilutive capital raises, signaling severe operational and financial instability.
Red Flags Detected (9)
Disclosure controls and procedures deemed ineffective as of June 30, 2026
Multiple material weaknesses identified: inadequate segregation of duties, insufficient technical accounting expertise, ITGC deficiencies including super-user access issues
Complete abandonment of core clinical trial program (Ropidoxuridine) in favor of speculative cryptocurrency mining venture
6 more red flags detected
Key Takeaways
Company has transformed from a radiosensitizer drug developer into a diversified holding company with crypto mining and AI software assets
Ineffective internal controls raise red flags for investors regarding financial statement reliability
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.